- 作者：Alexandr Poprach ; M.D. ; Ph.Da ; Tomas Pavlik ; Ph.Db ; Bohuslav Melichar ; M.D. ; Ph.Dc ; Katerina Kubackova ; M.D.d ; Zbynek Bortlicek ; Ph.D.b ; Marek Svoboda ; M.D. ; Ph.D.a ; Radek Lakomy ; M.D. ; Ph.D.a ; Rostislav Vyzula ; M.D. ; Ph.D.a ; Igor Kiss ; M.D. ; Ph.D.a ; Ladislav Dusek ; Ph.D.b ; Tomas Buchler ; M.D. ; Ph.D.e ; tomas.buchler@ftn.cz" class="auth_mail ; Czech Renal Cancer Cooperative Group
- 关键词：renal cell carcinoma ; prognosis ; survival ; sunitinib ; sorafenib
- 刊名：Urologic Oncology: Seminars and Original Investigations
- 出版年：May 2014
- 年：2014
- 卷：32
- 期：4
- 页码：488-495
- 全文大小：198 K
Materials and methods
A national database of patients treated with targeted agents was used as the data source. A total of 319 patients treated with sunitinib (n = 181) or sorafenib (n = 138) after progression on cytokine therapy were analyzed.
Results
Prognostic factors significantly associated with poor overall survival in a multivariable Cox model included the time from diagnosis to the start of treatment with TKIs<1 year, increased neutrophil counts, increased lactate dehydrogenase, and Eastern Oncology Cooperative Group performance status 2 or higher. The parameters showing statistically significant association with progression-free survival included time from diagnosis to the beginning of treatment with TKI<1 year, increased lactate dehydrogenase, and Eastern Oncology Cooperative Group performance status 2 or higher. We have also validated the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model in our cohort of patients.
Conclusion
We demonstrate that the International Database Consortium prognostic model performs well for European patients treated with TKIs, including sunitinib or sorafenib, after progression on cytokines and suggest that a reduction from original 6 down to 4 parameters is possible.